相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
Aaron N. Hata et al.
CANCER RESEARCH (2014)
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Nitin Jain et al.
CLINICAL CANCER RESEARCH (2014)
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia
Monique Dail et al.
NATURE (2014)
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Liran I. Shlush et al.
NATURE (2014)
The clinical development of MEK inhibitors
Yujie Zhao et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
M. Ryan Corces-Zimmerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
Omar Abdel-Wahab et al.
CANCER DISCOVERY (2014)
NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions
Jinyong Wang et al.
BLOOD (2013)
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran et al.
CANCER CELL (2013)
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice
Tiffany Chang et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic Transformation
Jin Xu et al.
CANCER DISCOVERY (2013)
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras
Jin Xu et al.
BLOOD (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group
Hirozumi Sano et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Junping Jing et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
Max Jan et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus
Qing Li et al.
BLOOD (2011)
Integrative prognostic risk score in acute myeloid leukemia with normal karyotype
Frederik Damm et al.
BLOOD (2011)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
Costa Bachas et al.
BLOOD (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
Small-molecule inhibition of APT1 affects Ras localization and signaling
Frank J. Dekker et al.
NATURE CHEMICAL BIOLOGY (2010)
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents
Monique Dail et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras
Jennifer O. Lauchle et al.
NATURE (2009)
Targeting Ras in myeloid leukemias
Benjamin S. Braun et al.
CLINICAL CANCER RESEARCH (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
Alan P. Brown et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert et al.
NATURE REVIEWS CANCER (2007)
Implications of NRAS mutations in AML:: a study of 2502 patients
Ulrike Bacher et al.
BLOOD (2006)
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
DT Bowen et al.
BLOOD (2005)
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells
MJ Kiel et al.
CELL (2005)
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia
LY Shih et al.
LEUKEMIA (2004)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
SC Kogan et al.
BLOOD (2002)
分享论文
